# Direct Oral Anticoagulant Management in Patients Undergoing Cardiac Implantable Electronic Device Procedures

#### $\bullet \bullet \bullet$

Michelle Alland, MSN FNP-C Marci Farquhar-Snow, MN CCRN CMC ACNP-BC AACC Department of Cardiovascular Diseases Mayo Clinic Phoenix, AZ

# Disclosures

- Marci Farquhar-Snow
  Nothing to disclose
  No conflict of interest
- Michelle Alland
  - Nothing to discloseNo conflict of interest



# **Abbreviations**

- AF Atrial fibrillation
- ASA Aspirin
- CIED Cardiac Implantable Electronic Devices -permanent pacemaker and/or implantable cardiodefibrillator
- DAPT Dual antiplatelet therapy -aspirin plus clopidogrel, ticagrelor, or prasugrel
- DOAC Direct Oral Anticoagulant -rivaroxaban, apixaban, dabigatran
- OAC Oral Anticoagulants

# Background

- Annually, 10-15% patients on OAC undergo procedures that require periprocedural management
- No US consensus guidelines for DOACs in periprocedural setting until recently (2017)
- 70% institutions do not have standardized protocols for periprocedural management of DOACs
- Overall OAC use rate increased from 52.4% to 60.7% among eligible AF patients

## Aims of Research

- Evaluate trends in periprocedural management of DOACs surrounding CIED procedures
- Evaluate longitudinal change in DOAC management practices
- Analyze factors contributing to decision-making process for DOAC management surrounding CIED procedures.
- Identify DOAC management strategies that are safe for patients undergoing CIED procedures.

### Part 1:

### Trends in DOAC Management in Patients Undergoing CIED Procedures

Marci Farquhar-Snow, MN CCRN CMC ACNP-BC AACC

Department of Cardiovascular Diseases Mayo Clinic, Phoenix, AZ



# **Objectives**

- 1. Describe research/recommendations for periprocedural management of DOACs surrounding CIED procedures
- 2. Evaluate practice trends in periprocedural management of DOACs surrounding CIED procedures

### **DOAC** Profiles

#### Dabigatran Direct thrombin inhibitor

- Onset: 1 hr
- Peak: 2-4 hr
- Half-life: 12-17 hr

Apixaban Factor Xa Inhibitor

- Onset: 3-4 hr
- Peak: 3-4 hr
- Half-life: 12 hr

Rivaroxaban Factor Xa Inhibitor

- Onset:
- Peak: 2-4 hr
- Half-life: 5-9 hr age 20-45 11-13hr age >45

### Package Recommended Hold Times

Dabigatran Direct thrombin inhibitor

- 1 to 2 days (CrCl >50mL/min) or
  3-5 days (CrCl < 50 mL/min)</li>
- "Consider longer times in major surgery, spinal puncture, or placement of a spinal or epidural catheter"

Apixaban Factor Xa Inhibitor

- At least 48 hours prior to procedures with a moderate to high risk of clinically significant bleeding
- At least 24 hours prior procedures with low risk of bleeding or where bleeding "non-critical and easily controlled"

#### Rivaroxaban Factor Xa Inhibitor

- At least 24 hours before surgical procedure to reduce the risk of bleeding
- "Increased risk of bleeding should be weighed against urgency of intervention"

### Methods


- Retrospective chart review
- All adult patients on DOACs at time of CIED procedure
- Mayo Clinic (Arizona, Jacksonville, Rochester) from January 2012 -June 2016
- N=309

### **Data Collected**


- Number of days DOAC held before and after procedure
- Frequency of bridging with heparin
- Comorbidities
- Concurrent medications
- CHA2DS2-VASc and HASBLED scores
- Age
- Procedure type
- Facility location
- Year
- Bleeding and thrombotic complication rates

#### DOAC Use: Trend 2012-2016


(Based on patients meeting study inclusion criteria)



### **Results: Periprocedural Management**



**Days to Hold DOAC After Procedure** 



### Summary of Trends

- Average # of days held prior to procedure: 2.2
- Average # of days held after procedure: 1.5
- Bridging rate with unfractionated heparin 8.3%
- No significant practice differences across three hospital sites between 2008-2014

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY © 2017 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER VOL. 69, NO. 7, 2017 ISSN 0735-1097/\$36.00 http://dx.doi.org/10.1016/j.jacc.2016.11.024

#### EXPERT CONSENSUS DECISION PATHWAY

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force

Thomas L. Ortel, MD, PHD Sherry J. Saxonhouse, MD, FACC Sarah A. Spinler, PHARMD, AACC

Task Force on Clinical Expert Consensus

Documents

Luis C. Afonso, MBBS, FACC Brendan Everett, MD, FACC Jonathan Halperin, MD, FACC Adrian Hernandez, MD, FACC William Hucker, MD Hani Jneid, MD, FACC Dharam Kumbhani, MD, SM, FACC

James L. Januzzi, Jr. MD. FACC, Chair

Eva M. Lonn, MD, FACC Joseph Marine, MD, FACC James K. Min, MD, FACC Pamela B. Morris, MD, FACC Robert Piana, MD, FACC John Puskas, MD, FACC Karol E. Watson, MD, FACC Barbara S. Wiggins, PhasmD, AACC <u>Guidance Statement</u> for interruption of a DOAC periprocedurally:

- 1. Interrupt therapy for low bleed-risk procedures in:
  - Patients treated with any of the approved DOACs for a duration based on the estimated CrCl (Table 2).
- Interrupt therapy for intermediate, high, or uncertain bleed-risk procedures in:
  - Patients treated with any of the approved DOACs for a duration based on the estimated CrCl (Table 2).

### **Part 2:**

### Factors Influencing Management of DOACs in Patients Undergoing CIED Procedures

Marci Farquhar-Snow, MN CCRN CMC ACNP-BC AACC

Department of Cardiovascular Diseases


Mayo Clinic, Phoenix, AZ



# **Objectives**

- Describe factors that impact bleeding and thrombotic risks for patients on OAC in the periprocedural setting
- 2. Analyze factors contributing to decision-making process regarding periprocedural management of DOACs

# Type of DOAC Used



## Type of Procedure Performed

- Pacemaker Implant
- ICD Implant
- 🖬 Bi-V Upgrade
- Lead Revision
- Pacemaker Generator Change
- ICD Generator Change
- 📔 Pacemaker Explant
- 🖬 ICD Explant
- Combination Procedure

Combination Procedure



### **Estimation of Risk**

### CHA<sub>2</sub>DS<sub>2</sub> VASc Score

### **HASBLED** Score

C	Congestive heart failure/LV dysfunction	1	Н	Hypertension	1
Η	Hypertension	1	Α	Abnormal renal and/or liver function	1 or 2
<b>A</b> 2	Age >75	2	S	Stroke	2
D	Diabetes mellitus	1	В	Bleeding tendency or predisposition	1
<b>S</b> 2	Stroke/TIA/thrombo-embolism	2	L	Labile INRs (for patients on warfarin)	2
۷	Vascular disease	1	E	Elderly (patients >65 years old)	1
A	Age 65-74	1	D	Drugs (cocomittant ASA or NSAIDs) and/or	1 or 2
Sc	Sex category (female)	1		alcohol abuse	


### **Estimation of Risk**

### CHA<sub>2</sub>DS<sub>2</sub> VASc Score

### HASBLED Score

Adjusted str	oke rate according to CHA <sub>2</sub> DS <sub>2</sub>	-VASc score				
CHA <sub>2</sub> DS <sub>2</sub> -VASc score	Patients (n = 7329)	Adjusted stroke rate (percent/year)*	HAS-BLED score (total points)	Bleeds per 100 patient-years*		
0	1	0 percent	0	1.13		
1	422	1.3 percent	0			
2	1230	2.2 percent	1	1.02		
3	1730	3.2 percent	_			
4	1718	4.0 percent	2	1.88		
5	1159	6.7 percent	3	3.74		
6	679	9.8 percent	5	5.74		
7	294	9.6 percent	4	8.70		
8	82	6.7 percent				
9	14	15.2 percent	5 to 9	Insufficient data		

### **Risk Scores by Age Group**



## **Statistical Analysis**

There was NO significant difference in **holding** DOAC prior based upon:

- Gender
- Comorbidities
- Concurrent ASA use
- Renal function
- CHADS2 VASc or HASBLED score
- Age

• Sex

	Dependent Variable = Days to Hold Prior to Procedure								
		Ν	Pct (%)	Mean (SD)	Range	p-value <sup>1</sup>			
Gender						0.379			
	Female	86	31.00%	2.4 (3.3)	0.0 - 30.0				
	Male	191	69.00%	2.1 (1.4)	0.0 - 9.0				
CAD / PAD						0.115			
	No	168	60.60%	2.4 (2.5)	0.0 - 30.0				
	Yes	109	39.40%	2.0 (1.4)	0.0 - 9.0				
PE / DVT						0.987			
	No	264	95.30%	2.2 (2.2)	0.0 - 30.0				
	Yes	13	4.70%	2.2 (1.5)	0.0 - 5.0				
Hypertension						0.309			
	No	99	35.70%	2.1 (1.3)	0.0 - 5.0				
	Yes	178	64.30%	2.3 (2.5)	0.0 - 30.0				
Afib / Aflutter						0.543			
	No	19	6.90%	2.1 (1.1)	0.0 - 4.0				
	Yes	258	93.10%	2.2 (2.2)	0.0 - 30.0				
CVA / TIA						0.752			
	No	239	86.30%	2.2 (2.2)	0.0 - 30.0				
	Yes	38	13.70%	2.3 (1.8)	0.0 - 9.0				
Thrombophilia						0.316			
	No	276	99.60%	2.1 (1.4)	0.0 - 9.0				
	Yes	1	0.40%	30.0 ()	30.0 - 30.0				
ASA						0.542			
	No	175	63.20%	2.3 (2.5)	0.0 - 30.0				
	Yes	102	36.80%	2.1 (1.4)	0.0 - 9.0				
DAPT				\/		0.055			
	No	268	96.80%	2.3 (2.2)	0.0 - 30.0				
	Yes	9	3.20%	1.3 (1.1)	0.0 - 3.0				
CKD Stage				~ /		0.484			
not check	ed/UTA	67	24.20%	1.9 (1.6)	0.0 - 9.0				
	60+	128	46.20%	2.4 (2.8)	0.0 - 30.0				
	30 - 59	78	28.20%	2.2 (1.4)	0.0 - 6.0				
	15 - 29	4	1.40%	2.3 (1.0)	1.0 - 3.0				
Age		277	100.00%	73.8 (10.7)	37.0 - 93.0	0.611			
Has Bled Score		277	100.00%	1.6 (0.9)	0.0 - 4.0	0.355			
CHADS2 VASc	Score	277	100.00%	3.6 (1.5)	0.0 - 8.0	0.566			

## **Statistical Analysis**

There was NO significant difference in **resuming DOAC** based upon:

- Gender
- Comorbidities
- Concurrent ASA use
- Renal function
- CHADS2 VASc or HASBLED score
- Age

• Sex

Dependent Variable = Days to Hold After Procedure								
	N Pct (%) Mean (SD) Range							
Gender						p-value <sup>1</sup> 0.711		
	Female	83	31.70%	1.6 (1.5)	0.0 - 7.0			
	Male	179	68.30%	1.5 (1.7)	0.0 - 14.0			
CAD / PAD						0.498		
	No	159	60.70%	1.6 (1.5)	0.0 -7.0			
	Yes	103	39.30%	1.4 (1.9)	0.0 - 14.0			
PE / DVT						0.247		
	No	247	94.30%	1.5 (1.7)	0.0 - 14.0			
	Yes	15	5.70%	1.9 (1.7)	0.0 - 6.0			
Hypertension						0.794		
	No	103	39.30%	1.6 (1.5)	0.0 - 7.0			
	Yes	159	60.70%	1.5 (1.8)	0.0 - 14.0			
Afib / Aflutter						0.236		
	No	19	7.30%	1.9 (1.5)	0.0 - 6.0			
	Yes	243	92.70%	1.5 (1.7)	0.0 - 14.0			
CVA / TIA						0.132		
	No	229	87.40%	1.5 (1.7)	0.0 - 14.0			
	Yes	33	12.60%	2.0 (1.7)	0.0 - 7.0			
Thrombophilia						N/A		
-	No	261	99.60%	1.5 (1.7)	0.0 - 14.0			
	Yes	1	0.40%	0.0()	0.0 - 0.0			
ASA						0.797		
	No	166	63.40%	1.6 (1.5)	0.0 - 7.0			
	Yes	96	36.60%	1.5 (1.9)	0.0 - 14.0			
DAPT						0.014		
	No	253	96.60%	1.6 (1.7)	0.0 - 14.0			
	Yes	9	3.40%	0.6 (0.7)	0.0 - 2.0			
CKD Stage						0.313		
not checke	d/UTA	247	94.30%	1.5 (1.6)	0.0 - 14.0			
	60+	3	1.10%	0.7 (1.2)	0.0 - 2.0			
	30 - 59	1	0.40%	6.0 ()	6.0 - 6.0			
	15 - 29	8	3.10%	1.1 (0.8)	0.0 - 3.0			
Age		262	100.00%	73.9 (10.5)	37.0 - 93.0	0.783		
Has Bled Score		262	100.00%	1.6 (0.8)	0.0 - 4.0	0.412		
CHADS2 VASe S	core	262	100.00%	3.5 (1.5)	0.0 - 7.0	0.155		



- Patients on DAPT had DOAC held significantly less days after the procedure.
- Patients receiving cardiodefibrillator had DOAC held significantly more days *after* the procedure.
- Patients receiving either pacemaker or defibrillator generator change had DOAC held significantly less days *after* the procedure.

### Part 3:

### Complication Rates Associated with DOACs in Patients Undergoing CIED Procedures

Michelle Alland, MSN FNP-C Department of Cardiovascular Diseases Mayo Clinic, Phoenix, AZ



# **Objectives**

- Describe bleeding and thrombotic complication rates for patient on DOAC in the periprocedural period surrounding CIEDs
- 2. Identify DOAC management strategies at lowest risk for complications surrounding CIED procedures


### **Current Literature**

- To our knowledge no studies published looking specifically at complications/outcomes of patients on DOACs at the time of CEID procedures
- Estimated bleeding complication rate after CEID implant in patients on warfarin ~2-4%

### **Current Literature**


Incidence of bleeding:

- ranged from 0.58% to 2.81% (mean 0.89%)
- ranged by type of pharmaceutical therapy



#### Combined incidence of bleeding complications:

- 274 of 5978 (4.6%)
- ranging from 2.2% (no therapy) to 14.6% (HBS)



Bernard et al, 2012 (Circulation EP)

### **Results:** Complications

- No thrombotic complications
- Three bleeding complications
  - Case 1: 71yo F, pacemaker generator change with LV lead addition, rivaroxaban held 1 day before and restarted the same day as the procedure. Not on ASA.
  - Case 2: 93yo M, pacemaker generator change, rivaroxaban not stopped, also on ASA.
  - Case 3: 73yo M, pacemaker generator change, rivaroxaban held 2 days before and 2 days after, also on ASA.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY © 2017 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION PUBLISHED BY ELSEVIER VOL. 69, NO. 7, 2017 ISSN 0735-1097/\$36.00 http://dx.doi.org/10.1016/j.jacc.2016.11.024

#### EXPERT CONSENSUS DECISION PATHWAY

2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force

Thomas L. Ortel, MD, PHD Sherry J. Saxonhouse, MD, FACC Sarah A. Spinler, PHARMD, AACC

Task Force on Clinical Expert Consensus

Documents

Luis C. Afonso, MBBS, FACC Brendan Everett, MD, FACC Jonathan Halperin, MD, FACC Adrian Hernandez, MD, FACC William Hucker, MD Hani Jneid, MD, FACC Dharam Kumbhani, MD, SM, FACC

James L. Januzzi, Jr. MD. FACC, Chair

Eva M. Lonn, MD, FACC Joseph Marine, MD, FACC James K. Min, MD, FACC Pamela B. Morris, MD, FACC Robert Piana, MD, FACC John Puskas, MD, FACC Karol E. Watson, MD, FACC Barbara S. Wiggins, PhasmD, AACC <u>Guidance Statement</u> for interruption of a DOAC periprocedurally:


- 1. Interrupt therapy for low bleed-risk procedures in:
  - Patients treated with any of the approved DOACs for a duration based on the estimated CrCl (Table 2).
- Interrupt therapy for intermediate, high, or uncertain bleed-risk procedures in:
  - Patients treated with any of the approved DOACs for a duration based on the estimated CrCl (Table 2).

## **Bleeding Risk Factors**

#### Doherty, 2017 (JACC)

TABLE 1	TABLE 1         Patient Bleed Risk Factors						
HAS-BLED parameters (52)*							
Hypertension	Hypertension†						
Abnormal rer	nal function‡						
Abnormal liv	er function§						
Prior stroke							
History of or	History of or predisposition to (anemia) major bleeding						
Labile INR (V	KA)						
Elderly (>65	Elderly (>65 years)						
Concomitant use of an antiplatelet agent or nonsteroidal anti-inflammatory drug							
Alcohol or drug usage history (≥8 drinks/week)¶							
Additional items included in the periprocedural management algorithm							
Prior bleed event within 3 months (including intracranial hemorrhagic)							
Quantitative or qualitative platelet abnormality							
INR above th	INR above the therapeutic range at the time of the procedure (VKA)						
Bleed history	Bleed history from previous bridging						

Bleed history with similar procedure



#### Doherty, 2017 (JACC)

### **ACC Consensus Recommendations**

### TABLE 2 Recommended Durations for Withholding DOACs Based on Procedural Bleed Risk and Estimated CrCl When There Are No Increased Patient Bleed Risk Factors

			Apixaban, Edoxaban, or Rivaroxaban						
CrCl, mL/min	≥80	50-79	30-49	15-29	<15	≥30	15-29	<15	
Estimated drug half-life, h	13	15	18	27	30 (off dialysis)	6-15	Apixaban: 17 Edoxaban: 17 Rivaroxaban: 9	Apixaban: 17 (off dialysis) Edoxaban: 10-17 (off dialysis) Rivaroxaban: 13 (off dialysis)	
Procedural bleed risk									
Low	≥24 h	≥36 h	≥48 h	≥72 h	No data. Consider measuring dTT and/or withholding ≥96 h.	≥24 h	≥36 h	No data. Consider measuring agent-specific anti Xa level and/or withholding ≥48 h	
Uncertain, intermediate, or high	≥48 h	≥72 h	≥96 h	≥120 h	No data. Consider measuring dTT.	≥48 h	No data. Consider measuring agent-specific anti level and/or withholding ≥72 h.		

NOTE: The duration for withholding is based upon the estimated DOAC half-life withholding times of 2 to 3 half-lives for low procedural bleeding risk and 4 to 5 drug half-lives for uncertain, intermediate, or high procedural bleeding risk (46,60–67).

CrCl = creatinine clearance; DOAC = direct-acting oral anticoagulant; dTT = dilute thrombin time.

#### Doherty, 2017 (JACC)

# Clinical Tool: AskMayoExpert

### Periprocedural anticoagulation management calculator


This tool will calculate the number of days prior to a procedure or surgery if an anticoagulant would need to be stopped.

Do not use this application if patient has had an acute venous thromboembolism within the last 4 weeks.

Planned date of surgery:



☆



Reset

Submit

#### Care Recommendation

For surgery on 08/04/2017, the last dose of Apixaban (Eliquis) should be given on **Tuesday, 8/1/2017**.

No role for low molecular weight heparin bridging.



Warning: Epidural catheters or neuroaxial anesthesia

Warning: There is a high risk of bleeding complications with direct oral anticoagulants prior to the use of epidural catheters or neuroaxial anesthesia (See US FDA warning)

# Conclusions

- Overall, CIED procedures in patients treated with DOACs appear to have a low complication rate of bleeding or thrombosis; regardless of DOAC management strategy.
- No correlation with CHADS2VASc and HASBLED scores relating to bleeding or thrombosis (though data limited)

### **Future Implications**

- Prospective study to evaluate bleeding complication rates with uninterrupted DOAC administration
- Prospective study comparing complication rates with warfarin versus DOAC use in CIED procedures.
- Evaluate trends in management between physician providers or advanced practice providers.
- Development of standardized consensus guidelines
- Investigate difference in management strategies in various geographical areas

# Next Steps

### Contact:

Alland.michelle@mayo.edu

Farquharsnow.marci@mayo.edu



### References

- Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012). Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2), e44S-e88s.
- Baron, T. H., Kamath, P. S., & McBane, R. D. (2013). Management of antithrombotic therapy in patients undergoing invasive procedures. The New England Journal of Medicine, 368(22), 2113-2124.
- Bernard, M., Shotwell, M., Nietert, P., & Gold, M. (2012) . Meta-Analysis of Bleeding Complications Associated With Cardiac Rhythm Device Implantation. Circulation: Arrhythmia and Electrophysiology. 2012;5:468-474..
- Beyer-Westendorf, J., Gelbricht, V., Förster, K., Ebertz, F., Köhler, C., Werth, S., Weiss, N. (2014). Peri-interventional management of novel oral anticoagulants in daily care: Results from the prospective Dresden NOAC registry. European Heart Journal, 35(28), 1888-1896.
- Daniels, P. R. (2015). Peri-procedural management of patients taking oral anticoagulants. BMJ, 351(8018), h2391.
- Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Kunz, R. (2012). Perioperative management of antithrombotic therapy: Antithrombotic therapy, and prevention of thrombosis, 9<sup>th</sup> ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 141(2\_suppl), e326S-e350S.
- Doherty, J., Gluckman,, T., Hucker,, W., Januzzi, J., Ortel, T., Saxonhouse, S., Spinler, S. 2017 ACC Expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: A report of the American College of Cardiology Clinical Expert Consensus Document Task Force; 69, (7), 871-91.
- Flake, G. C., Theriot, P., Binder, L. G., Dobesh, P. P., Cuker, A., & Doherty, J. U. (2016). Management of periprocedural anticoagulation: A survey of contemporary practice. Journal of the American College of Cardiology, 68(2).
- Garcia, D., Alexander, J. H., Wallentin, L., Wojdyla, D. M., Thomas, L., Hanna, M., Lopes, R. D. (2014). Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood, 124(25), 3692-3698.
- Healey, J. S., Eikelboom, J., Douketis, J., Wallentin, L., Oldgren, J., Yang, S., Ezekowitz, M. (2012). Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation, 126(3), 343-348.
- Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Kichof, P. (2013). European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15(5), 625-651.
- Marzec, L, et al Influence of DOACs on rates of oral anticoagulation for AF. JACC 69(20) 2475-84.
- Nichols, C. And Vose, J. (2017). Incidence of Bleeding-Related Complications During Primary Implantation and Replacement of Cardiac Implantable Electronic Devices. Journal of the American Heart Association. 2017;6:e004263.
- Oktay, E. (2015). Will NOACs become the new standard of care in anticoagulation therapy? International Journal of the Cardiovascular Academy, 1(1), 1-4.
- Schulman, S., Carrier, M., Lee, A. Y. Y., Shivakumar, S., Blostein, M., Spencer, F. A.Douketis, J. D. (2015). Perioperative management of dabigatran: A prospective cohort study. Circulation, 132(3), 167-173.
- Sherwood, M. W., Douketis, J. D., Patel, M. R., Piccini, J. P., Hellkamp, A. S., Lokhnygina, Y., Becker, R. C. (2014). Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation, 129(18), 1850-1859.